Torrent Pharmaceuticals Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 7 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.8L Cr
India business continues to outperform market growth with 12-13% revenue growth YTD; focus on cardiac, diabetes, and gastro drives growth. Operating EBITDA margin expected to sustain at about 32.5% in Q4 FY25.
From Torrent Pharmaceuticals Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹4,896
Market Cap
₹1.8L Cr
P/E Ratio
82.4
How does Torrent Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Torrent Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Torrent Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹4.2K Cr, net profit ₹364 Cr.
Full financials →📊 Revenue & Sales Performance
- →India business continues to outperform market growth with 12-13% revenue growth YTD; focus on cardiac, diabetes, and gastro drives growth.
- →Chronic business in India grew 14% vs. IPM 10%, aided by new product launches and expanded field force.
- →Brazil market expected to maintain double-digit growth (~10-12% constant currency); government price hikes anticipated to offset currency depreciation.
- →Germany business to see growth from new tenders starting Q2 next year; expect continued high single-digit growth.
- →US business stable but slow pickup expected short-term; growth dependent on new ANDA filings.
- →Overall, company projects 7% underlying revenue growth normalized for insulin business and currency impact in Q3.
- →Operating EBITDA margin expected to improve 50-100 bps annually, supported by branded business growth and US launches next year.
- →Insulin business expected to recover with Q4 showing spillover above Rs. 75-80 crore quarterly run rate.
📈 Profitability & Margins
- →Operating EBITDA margin expected to sustain at about 32.5% in Q4 FY25.
- →Full year FY25 operating EBITDA margin is anticipated to improve to around 32.5% from 31.4% last year (110 bps improvement).
- →Margin improvement guidance of 50 to 100 basis points per year expected to continue going forward.
- →FY26 margin to improve by 50 to 100 bps, driven by branded segment contribution and expected US launches reducing negative contribution.
- →Insulin business expected to return to normal run rate (Rs. 75-80 crore per quarter) plus spillover revenue in Q4.
- →Brazil to continue double-digit constant currency growth with expected government price revisions in April 2025.
- →India branded business to continue outperforming market growth (~12-13% YTD) with focus on cardiac, diabetes, gastro.
- →Net debt to EBITDA expected to reduce, with company likely to turn net cash positive by first half FY27.
🏗️ Capital Expenditure Plans
- →Sudhir Menon mentioned that the company's capital allocation priorities and strategic investments are still a work in progress, with specific details expected in a couple of quarters.
- →The top priority for capital allocation remains India, especially branded generics, where the company has the best track record and highest comfort.
- →They remain open to opportunities in developed markets like Germany and the US in specified areas.
- →There was mention of reinvestment happening in the branded business which could impact margin improvements, indicating ongoing or planned investments.
- →The company is also making investments in market formation activities such as information dissemination and education for new product launches.
- →No specific new capex or strategic transaction details were disclosed at this stage.
💰 Fundraising & Capital Structure
- →No explicit mention of any new fundraising through debt or equity in the current quarter or near future.
- →Sudhir Menon indicated that the company expects to become net cash positive by H1 FY27 due to ongoing repayments.
- →Interest expenses are expected to continue decreasing quarter-on-quarter because of these repayments.
- →Discussions on capital allocation priorities are still a work in progress, with more clarity expected in a couple of quarters.
- →The company prioritizes investments in India branded generics, followed by selective opportunities in international developed markets.
- →No specific plans or announcements regarding raising fresh debt or equity were disclosed during the call.
📋 Order Book & Pipeline
- →The document does not explicitly mention the current or expected order book or pending orders for Torrent Pharmaceuticals.
- →However, highlights on product launches and market expectations are noted:
- → - In Brazil and India, plans to launch GLP-1 products are aligned with patent expiry in March 2026, aiming to be in the first wave of launches.
- → - Brazil has a rich pipeline of 20 molecules filed and awaiting ANVISA approval.
- → - Germany business won incremental new tenders starting to contribute from Q2 FY26.
- →Focus remains on market formation activities and education for new products, indicating pipeline and upcoming opportunities.
- →No specific quantitative data on order book or pending orders provided during the Q3 FY25 call.
Key Metrics
Frequently Asked Questions
What were Torrent Pharmaceuticals Ltd Q3 FY25 results?
India business continues to outperform market growth with 12-13% revenue growth YTD; focus on cardiac, diabetes, and gastro drives growth. Operating EBITDA margin expected to sustain at about 32.5% in Q4 FY25.
What is Torrent Pharmaceuticals Ltd share price analysis?
Torrent Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 82.4 with a market cap of ₹183,832 Cr. Investors should review the full earnings analysis for detailed insights.
Is Torrent Pharmaceuticals Ltd planning capital expenditure?
Sudhir Menon mentioned that the company's capital allocation priorities and strategic investments are still a work in progress, with specific details expected in a couple of quarters.
Keep Torrent Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.